

DAFTAR PUSTAKA

- American Heart Association, 2015. 'All About Heart Rate (Pulse)', . URL: http://www.heart.org/HEARTORG/Conditions/HighBloodPressure/GettheFactsAboutHighBloodPressure/All-About-Heart-Rate-Pulse_UCM_438850_Article.jsp#.WyEdhfUxWUk (diakses tanggal 13/6/2018).
- American Pharmacists Association, 2008. AHFS Drug Information 2008.chm.
- Anderson, R., Breunig, K., Foundling, P., Johnson, R., Smith, L., dan Sundstrom, M., 2015. Body Position and its Effect on Heart Rate, Blood Pressure, and Respiration Rate After Induced Acute Mental Stress. *Departemen of Physiology, University of Wisconsin-Madison*, .
- Andrén, L., Höglund, P., Dotevall, A., Eggertsen, R., Svensson, A., Olson, S.-O., dkk., 1988. Diltiazem in hypertensive patients with type II diabetes mellitus. *The American Journal of Cardiology*, **62**: 114–120.
- Angiolillo, D.J., 2009. Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future Directions. *Diabetes Care*, **32**: 531–540.
- Annex III-Summary of Product Characteristics, 2013. *Product Information as Approved by the CHM*.
- Ansari, J.A., 2010. Drug Interaction and Pharmacist. *Journal of Young Pharmacists*, **2**: 326–331.
- Armahizer, M.J., Kane-Gill, S.L., Smithburger, P.L., Anthes, A.M., dan Seybert, A.L., 2013. Comparing Drug-Drug Interaction Severity Ratings between Bedside Clinicians and Proprietary Databases. *ISRN Critical Care*, **2013**: 1–6.
- Ashley, C., Currie, A., dan Burns, A. (Editor), 2009. *The Renal Drug Handbook*, 3. ed. ed. Radcliffe, Oxford.
- Astrand, P. dan Rodahl, 1986. *Textbook of Work Physiology*, Edisi Ketiga. ed. McGraw-Hill Book Company, New York.
- Baciewicz, A.M. dan Baciewicz, F.A., 1989. Effect of cimetidine and ranitidine on cardiovascular drugs. *American Heart Journal*, **118**: 144–154.
- Baillie, T.A. dan Rettie, A.E., 2011. Role of Biotransformation in Drug-Induced Toxicity: Influence of Intra- and Inter-Species Differences in Drug Metabolism. *Drug Metabolism and Pharmacokinetics*, **26**: 15–29.
- Barnes, B.J. dan Hollands, J.M., 2010. Drug-induced arrhythmias: *Critical Care Medicine*, **38**: S188–S197.
- Barnett, A.G., Sans, S., Salomaa, V., Kuulasmaa, K., dan Dobson, A.J., 2007. The effect of temperature on systolic blood pressure: *Blood Pressure Monitoring*, **12**: 195–203.

- Bedenis, R., Stewart, M., Cleanthis, M., Robless, P., Mikhailidis, D.P., dan Stansby, G., 2014. Cilostazol for intermittent claudication, dalam: The Cochrane Collaboration (Editor), *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd, Chichester, UK.
- Bramer, S.L., Forbes, W.P., dan Mallikaarjun, S., 1999. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. *Clinical Pharmacokinetics*, **37 Suppl 2**: 1–11.
- Briggs, G.C., 2012. *Pharmacogenomic Testing in Clinical Practice*. GENETWORx.
- Bryant, L., 2009. Clinically important drug–drug interactions and how to manage them. *Journal of Primary Health Care*, **1**: 4.
- Bums, J.J. dan Conney, A.H., 1965. Enzyme Stimulation and Inhibition in the Metabolism of Drugs. *Proceedings of the Royal Society of Medicine*, **58**: 955–960.
- Burton, D.A., Stokes, K., dan Hall, G.M., 2004. Physiological effects of exercise. *Continuing Education in Anaesthesia Critical Care & Pain*, **4**: 185–188.
- Calzolari, D., Bruschi, S., Coquin, L., Schofield, J., Feala, J.D., Reed, J.C., dkk., 2008. Search Algorithms as a Framework for the Optimization of Drug Combinations. *PLoS Computational Biology*, **4**: e1000249.
- Cascorbi, I., 2012. Drug Interactions. *Deutsches Aerzteblatt Online*, .
- Chapman, T.M. dan Goa, K.L., 2003. Cilostazol: a review of its use in intermittent claudication. *American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions*, **3**: 117–138.
- Chen, L. dan Cheung, W.Y., 2014. Potential drug interactions in patients with a history of cancer. *Current Oncology*, **21**: 212.
- Cheung, B.M.Y. dan Li, C., 2012. Diabetes and Hypertension: Is There a Common Metabolic Pathway? *Current Atherosclerosis Reports*, **14**: 160–166.
- Chi, Y.-W., Lavie, C.J., Milani, R.V., dan White, C.J., 2008. Safety and Efficacy of Cilostazol in the Management of Intermittent Claudication. *Vascular health and risk management*, **4**: 1197–1203.
- Chiha, M., Njeim, M., dan Chedrawy, E.G., 2012. Diabetes and Coronary Heart Disease: A Risk Factor for the Global Epidemic. *International Journal of Hypertension*, **2012**: 1–7.
- Commissioner, O. of the, n.d. 'Reporting Serious Problems to FDA - What is a Serious Adverse Event?', , *WebContent*, . URL: <https://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm> (diakses tanggal 6/7/2018).

- Corbett, A.H., Dana, W.J., Fuller, M.A., Gallagher, J.C., Golembiewski, J.A., Gonzales, J.P., dkk. (Editor), 2015. *Drug Information Handbook*, 24th ed. Lexi-Comp Inc for American Pharmacists Association.
- Custodis, F., Reil, J.-C., Laufs, U., dan Böhm, M., 2013. Heart rate: A global target for cardiovascular disease and therapy along the cardiovascular disease continuum. *Journal of Cardiology*, **62**: 183–187.
- Davies, P. dan Maconochie, I., 2009. The relationship between body temperature, heart rate and respiratory rate in children. *Emergency Medicine Journal*, **26**: 641–643.
- Dawson, D.L., Cutler, B.S., Meissner, M.H., dan Strandness, D.E., 1998. Cilostazol Has Beneficial Effects in Treatment of Intermittent Claudication : Results From a Multicenter, Randomized, Prospective, Double-blind Trial. *Circulation*, **98**: 678–686.
- de Franciscis, S., Gallelli, L., Battaglia, L., Molinari, V., Montemurro, R., Stillitano, D.M., dkk., 2015. Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease: Cilostazol and diabetic patients. *International Wound Journal*, **12**: 250–253.
- Dresser, G.K., Spence, J.D., dan Bailey, D.G., 2000. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. *Clinical pharmacokinetics*, **38**: 41–57.
- Duerden, M., Avery, T., Payne, R., dan King's Fund (London, E., 2013. *Polypharmacy and Medicines Optimisation: Making It Safe and Sound*.
- Elam, M.B., Heckman, J., Crouse, J.R., Hunninghake, D.B., Herd, J.A., Davidsson, M., dkk., 1998. Effect of the Novel Antiplatelet Agent Cilostazol on Plasma Lipoproteins in Patients With Intermittent Claudication. *Arteriosclerosis Thrombosis and Vascular Biology*, **18**: 1942–1947.
- Ewing, D.J., Campbell, I.W., dan Clarke, B.F., 1981. Heart Rate Changes in Diabetes Mellitus. *The Lancet*, 183–185.
- Ferner, R.E. dan Aronson, J.K., 2006. Communicating information about drug safety. *BMJ*, **333**: 143–145.
- Gerstein, M.B., Kundaje, A., Hariharan, M., Landt, S.G., Yan, K.-K., Cheng, C., dkk., 2012. Architecture of the human regulatory network derived from ENCODE data. *Nature*, **489**: 91–100.
- Goernig, M., Schroeder, R., Roth, T., Truebner, S., Palutke, I., Figulla, H.R., dkk., 2008. Peripheral Arterial Disease Alters Heart Rate Variability in Cardiovascular Patients. *Pacing and Clinical Electrophysiology*, **31**: 858–862.
- Green, P.J., Kirby, R., dan Suls, J., 1996. The effects of caffeine on blood pressure and heart rate: A review. *Annals of Behavioral Medicine*, **18**: 201–216.

- Guengerich, F.P., 2008. Cytochrome P450 and Chemical Toxicology. *Chemical Research in Toxicology*, **21**: 70–83.
- Gujjarlamudi, H., 2016. Polytherapy and drug interactions in elderly. *Journal of Mid-Life Health*, .
- Guyton, 1990. *Fisiologi Manusia Dan Mekanisme Penyakit Edisi III*. EGC, Jakarta.
- Hall, R. dan Mazer, C.D., 2011. Antiplatelet Drugs: A Review of Their Pharmacology and Management in the Perioperative Period. *Anesthesia & Analgesia*, **112**: 292–318.
- Hamilton, B.P., 1990. Diabetes mellitus and hypertension. *American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation*, **16**: 20–29.
- Hermawan, L., Subiyono, H.S., dan Rahayu, S., 2012. Pengaruh Pemberian Asupan Cairan (Air) Terhadap Profil Denyut Jantung Pada Aktivitas Aerobik 7.
- Hiatt, W.R., 2005. The US experience with cilostazol in treating intermittent claudication. *Atherosclerosis Supplements*, **6**: 21–31.
- Hori, M. dan Okamoto, H., 2012. Heart rate as a target of treatment of chronic heart failure. *Journal of Cardiology*, **60**: 86–90.
- Horn, J.R. dan Hansten, P.D., 2008. Get to Know an Enzyme: CYP3A4. *Pharmacy Times*, 40–42.
- Houghton, D., Jones, T.W., Cassidy, S., Siervo, M., MacGowan, G.A., Trenell, M.I., dkk., 2016. The effect of age on the relationship between cardiac and vascular function. *Mechanisms of Ageing and Development*, **153**: 1–6.
- Jameson, J., Dennis, L.K., dan Harrison, 2005. *Harrison's Principles of Internal Medicine*. McGraw-Hill Medical Publishing Division, New York.
- Juurink, D.N., 2003. Drug-Drug Interactions Among Elderly Patients Hospitalized for Drug Toxicity. *JAMA*, **289**: 1652.
- Kasenda, I., Marunduh, S., dan Wungouw, H., 2014. Perbandingan Denyut Nadi Antara Penduduk Yang Tinggal Di Dataran Tinggi Dan Dataran Rendah **2**: 6.
- Koraćević, G.P., Dakić, S.S., Veličković-Radovanović, R.M., Apostolović, S.R., Krstić, N.H., Tasić, I.S., dkk., 2015. Amlodipine as an antiischemic drug is superior to long acting nitrates. *Open Medicine*, **10**: .
- Kullo, I.J. dan Rooke, T.W., 2016. Peripheral Artery Disease. *New England Journal of Medicine*, **374**: 861–871.
- Lal, H.M. dan Lal, U., 2008. Drug Interactions - Mechanisms and Clinical Implications. *Medicine Update*, **18**: 17.
- Leé, S., 2016. 'Monitoring and optimizing antiplatelet therapy in patients undergoing percutaneous coronary intervention', . Semmelweis University, Budapest.

- Long, J., Lynch, J., Machiran, N., Thomas, S., dan Malinow, K., 1982. The Effect of Status on Blood Pressure During Verbal Communication. *Journal of Behavioral Medicine*, **5**: 165–172.
- Mallet, L., Spinewine, A., dan Huang, A., 2007. The challenge of managing drug interactions in elderly people **370**: 7.
- Mallikaarjun, S. dan Bramer, S.L., 1999. Effect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin. *Clinical Pharmacokinetics*, **37 Suppl 2**: 79–86.
- Melamed, S., 1987. Emotional Reactivity and Elevated Blood Pressure. *Psychosomatic Medicine*, **49**: 217–225.
- Mousa, O., Brater, D., Sundblad, K., dan Hall, S., 2000. The interaction of diltiazem with simvastatin. *Clinical Pharmacology & Therapeutics*, **67**: 267–274.
- National Heart, Lung, and Blood Institute, 2003. *Your Guide to Lowering Blood Pressure*. National Institutes of Health, Bethesda.
- Omvik, P., 1996. How Smoking Affects Blood Pressure. *Blood Pressure*, **5**: 71–77.
- Opie, L.H., 1988. Calcium channel antagonists part IV: Side effects and contraindications drug interactions and combinations. *Cardiovascular Drugs and Therapy*, **2**: 177–189.
- Palleria, C., Paolo, A.D., Giofrè, C., Leuzzi, G., Siniscalchi, A., Giovambattista D Sarro, dkk., 2013. Pharmacokinetic Drug-Drug Interaction and Their Implication in Clinical Management. *Journal of Research in Medical Sciences*, **18**: 601–610.
- Patel, J.J. dan Whittaker, C.T., 2007. Tachycardia-Induced Heart Failure. *The Permanente Journal*, **11**: 3.
- Pearce, E.C., 1999. *Anatomi Dan Fisiologi Untuk Para Medis*, Cetakan Keduapuluh Sembilan. ed. PT. Gramedia Pustaka Utama, Jakarta.
- Pham, T., 2003. Gender differences in cardiac development: are hormones at the heart of the matter? *Cardiovascular Research*, **57**: 591–593.
- Pool, P., Massie, B.M., Venkataraman, K., Hirsch, A.T., Samant, D.R., Seagren, S.C., dkk., 1986. Diltiazem Monotherapy for Systemic Hypertension: A Multicenter, Randomized, Placebo-Controlled Trial. *The American Journal of Cardiology*, **57**: 212–217.
- Prybys, K., Melville, K., dan Hanna, J., 2002. Polypharmacy in the elderly: Clinical Challenges in emergency practice: Part 1: Overview, etiology, and drug interactions. *Emergency Medicine Reports*, **23**: 145–153.
- Resnick, M.S., Maitland, L.A., dan Morgan, K.G., 1991. Flosequinan, a vasodilator with a novel mechanism of action. *British Journal of Pharmacology*, **102**: 974–978.
- Rodríguez Padial, L., Barón-Esquivias, G., Hernández Madrid, A., Marzal Martín, D., Pallarés-Carratalá, V., dan de la Sierra, A., 2016. Clinical Experience

- with Diltiazem in the Treatment of Cardiovascular Diseases. *Cardiology and Therapy*, **5**: 75–82.
- Saccò, M., Meschi, M., Regolisti, G., Detrenis, S., Bianchi, L., Bertorelli, M., dkk., 2013. The Relationship Between Blood Pressure and Pain. *The Journal of Clinical Hypertension*, **15**: 600–605.
- Schatz, S. dan Weber, R., 2015. Adverse drug reactions. *ACCP (American College of Clinical Pharmacy). CNS/Pharmacy Practice, PSAP*, .
- Shah, B.M. dan Hajjar, E.R., 2012. Polypharmacy, Adverse Drug Reactions, and Geriatric Syndromes. *Clinics in Geriatric Medicine*, **28**: 173–186.
- Siddiqui, A., 2011. Effects of Vasodilation and Arterial Resistance on Cardiac Output. *Journal of Clinical & Experimental Cardiology*, **02**: .
- Siswanto, 1987. *Tekanan Panas*. Balai Hiperkes dan Keselamatan Kerja Jawa Timur, Surabaya.
- Sowers, J.R., Khoury, S., Standley, P., Zemel, P., dan Zemel, M., 1991. Mechanisms of hypertension in diabetes. *American Journal of Hypertension*, **4**: 177–182.
- Sutton, D., Butler, A.M., Nadin, L., dan Murray, M., 1997. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. *Journal of Pharmacology and Experimental Therapeutics*, **282**: 294–300.
- Taggart, P., Boyett, M.R., Logantha, S., dan Lambiase, P.D., 2011. Anger, Emotion, and Arrhythmias: From Brain to Heart. *Frontiers in Physiology*, **2**: .
- Tatro, D.S., 2006. *Drug Interaction Fact*, 5th ed. Wolter Kluwer Company, California.
- Velez, L.I., Yi Feng, S., Goto, C.S., dan Benitez, F.L., 2011. Dangerous Drug Interactions. *Emergency Medicine*, **32**: .
- Verma, A., Prasad, A., Elkadi, G.H., dan Chi, Y.-W., 2011. Peripheral arterial disease: evaluation, risk factor modification, and medical management. *JCOM*, **18**: 74–84.
- Vivian, E.M. dan Rubinstein, G.B., 2002. Pharmacologic management of diabetic nephropathy. *Clinical Therapeutics*, **24**: 1741–1756; discussion 1719.
- Weintraub, W.S., 2006. The vascular effects of cilostazol. *Canadian Journal of Cardiology*, **22**: 56B-60B.
- Welling, P.G., 1984. Interactions Affecting Drug Absorption: *Clinical Pharmacokinetics*, **9**: 404–434.
- Yasin, N., Widyastuti, H., dan Dewi, E., 2005. Kajian Interaksi Obat Pada Pasien Gagal Jantung Kongestif Di RSUP Dr Sardjito Tahun 2005. *Majalah Farmasi Indonesia*, **3**: 15–22.

Zhou, S.-F., 2008. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. *Current drug metabolism*, **9**: 310–322.